Biocryst Pharmaceuticals Stock Shares Owned By Insiders

BCRX Stock

USD 7.50 0.01 0.13%

BioCryst Pharmaceuticals fundamentals help investors to digest information that contributes to BioCryst Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BioCryst Stock. The fundamental analysis module provides a way to measure BioCryst Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioCryst Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioCryst Pharmaceuticals Company Shares Owned By Insiders Analysis

BioCryst Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current BioCryst Pharmaceuticals Shares Owned By Insiders

1.15 %

Most of BioCryst Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioCryst Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BioCryst Shares Owned By Insiders Driver Correlations

Understanding the fundamental principles of building solid financial models for BioCryst Pharmaceuticals is extremely important. It helps to project a fair market value of BioCryst Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since BioCryst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioCryst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioCryst Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Current Deferred Revenue	Property Plant Equipment	Net Receivables	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.63	0.71	-0.94	0.91	0.95	1.0	-0.66	0.64	0.93	-0.3	0.87	0.79	-0.8	0.93	0.93	0.85	-0.65	-0.29	0.24	0.93	0.95	0.93
Total Stockholder Equity	-0.63		-0.07	0.58	-0.61	-0.44	-0.61	0.11	0.0	-0.66	0.43	-0.5	-0.22	0.27	-0.38	-0.47	-0.74	0.58	0.05	-0.07	-0.63	-0.65	-0.56
Net Debt	0.71	-0.07		-0.79	0.53	0.88	0.71	-0.69	0.95	0.65	-0.13	0.77	0.89	-0.9	0.9	0.74	0.49	-0.34	-0.33	0.34	0.59	0.6	0.68
Retained Earnings	-0.94	0.58	-0.79		-0.88	-0.95	-0.94	0.52	-0.77	-0.97	0.43	-0.89	-0.78	0.77	-0.91	-0.91	-0.87	0.67	0.36	-0.4	-0.8	-0.84	-0.93
Accounts Payable	0.91	-0.61	0.53	-0.88		0.83	0.92	-0.48	0.5	0.93	-0.34	0.79	0.63	-0.59	0.78	0.87	0.84	-0.6	-0.39	0.31	0.82	0.85	0.91
Total Liab	0.95	-0.44	0.88	-0.95	0.83		0.96	-0.74	0.8	0.89	-0.23	0.88	0.89	-0.9	0.99	0.95	0.76	-0.54	-0.39	0.26	0.87	0.89	0.92
Total Current Assets	1.0	-0.61	0.71	-0.94	0.92	0.96		-0.68	0.63	0.93	-0.27	0.87	0.8	-0.81	0.93	0.95	0.85	-0.64	-0.36	0.24	0.94	0.96	0.95
Short Term Debt	-0.66	0.11	-0.69	0.52	-0.48	-0.74	-0.68		-0.53	-0.43	-0.4	-0.63	-0.84	0.83	-0.8	-0.71	-0.39	0.16	0.29	0.08	-0.76	-0.74	-0.62
Short Term Investments	0.64	0.0	0.95	-0.77	0.5	0.8	0.63	-0.53		0.66	-0.16	0.74	0.8	-0.73	0.8	0.69	0.48	-0.41	-0.29	0.46	0.44	0.46	0.64
Common Stock	0.93	-0.66	0.65	-0.97	0.93	0.89	0.93	-0.43	0.66		-0.4	0.86	0.72	-0.64	0.82	0.89	0.9	-0.74	-0.37	0.46	0.77	0.82	0.94
Current Deferred Revenue	-0.3	0.43	-0.13	0.43	-0.34	-0.23	-0.27	-0.4	-0.16	-0.4		-0.19	0.13	0.09	-0.16	-0.16	-0.33	0.31	0.01	-0.14	-0.16	-0.18	-0.21
Property Plant Equipment	0.87	-0.5	0.77	-0.89	0.79	0.88	0.87	-0.63	0.74	0.86	-0.19		0.8	-0.74	0.86	0.82	0.79	-0.52	-0.27	0.38	0.75	0.77	0.8
Net Receivables	0.79	-0.22	0.89	-0.78	0.63	0.89	0.8	-0.84	0.8	0.72	0.13	0.8		-0.89	0.92	0.82	0.6	-0.42	-0.38	0.34	0.72	0.74	0.81
Net Tangible Assets	-0.8	0.27	-0.9	0.77	-0.59	-0.9	-0.81	0.83	-0.73	-0.64	0.09	-0.74	-0.89		-0.95	-0.81	-0.53	0.29	0.4	-0.08	-0.81	-0.81	-0.75
Long Term Debt	0.93	-0.38	0.9	-0.91	0.78	0.99	0.93	-0.8	0.8	0.82	-0.16	0.86	0.92	-0.95		0.93	0.7	-0.49	-0.39	0.24	0.87	0.88	0.88
Long Term Debt Total	0.93	-0.47	0.74	-0.91	0.87	0.95	0.95	-0.71	0.69	0.89	-0.16	0.82	0.82	-0.81	0.93		0.77	-0.56	-0.54	0.23	0.88	0.9	0.96
Capital Surpluse	0.85	-0.74	0.49	-0.87	0.84	0.76	0.85	-0.39	0.48	0.9	-0.33	0.79	0.6	-0.53	0.7	0.77		-0.73	-0.23	0.37	0.77	0.82	0.87
Deferred Long Term Liab	-0.65	0.58	-0.34	0.67	-0.6	-0.54	-0.64	0.16	-0.41	-0.74	0.31	-0.52	-0.42	0.29	-0.49	-0.56	-0.73		0.15	-0.63	-0.48	-0.53	-0.62
Long Term Investments	-0.29	0.05	-0.33	0.36	-0.39	-0.39	-0.36	0.29	-0.29	-0.37	0.01	-0.27	-0.38	0.4	-0.39	-0.54	-0.23	0.15		-0.25	-0.31	-0.34	-0.49
Short Long Term Debt	0.24	-0.07	0.34	-0.4	0.31	0.26	0.24	0.08	0.46	0.46	-0.14	0.38	0.34	-0.08	0.24	0.23	0.37	-0.63	-0.25		-0.02	0.04	0.32
Net Invested Capital	0.93	-0.63	0.59	-0.8	0.82	0.87	0.94	-0.76	0.44	0.77	-0.16	0.75	0.72	-0.81	0.87	0.88	0.77	-0.48	-0.31	-0.02		1.0	0.87
Net Working Capital	0.95	-0.65	0.6	-0.84	0.85	0.89	0.96	-0.74	0.46	0.82	-0.18	0.77	0.74	-0.81	0.88	0.9	0.82	-0.53	-0.34	0.04	1.0		0.9
Capital Stock	0.93	-0.56	0.68	-0.93	0.91	0.92	0.95	-0.62	0.64	0.94	-0.21	0.8	0.81	-0.75	0.88	0.96	0.87	-0.62	-0.49	0.32	0.87	0.9

Click cells to compare fundamentals

Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Competition

Predict BioCryst Pharmaceuticals

Based on the latest financial disclosure, 1.148% of BioCryst Pharmaceuticals are shares owned by insiders. This is 92.44% lower than that of the Biotechnology sector and 91.9% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 88.62% higher than that of the company.

BioCryst Shares Owned By Insiders Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioCryst Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics of similar companies.

BioCryst Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.

BioCryst Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioCryst Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioCryst Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

BioCryst Fundamentals

	Return On Equity	-19.25
	Return On Asset	-0.0425
	Profit Margin	(0.30) %
	Operating Margin	0.07 %
	Current Valuation	2.03 B
	Shares Outstanding	207.13 M
	Shares Owned By Insiders	1.15 %
	Shares Owned By Institutions	85.98 %
	Number Of Shares Shorted	20.83 M
	Price To Earning	(7.11) X
	Price To Book	56.59 X
	Price To Sales	3.76 X
	Revenue	331.41 M
	Gross Profit	10.94 M
	EBITDA	(116.33 M)
	Net Income	(226.54 M)
	Cash And Equivalents	417.48 M
	Cash Per Share	2.24 X
	Total Debt	848.71 M
	Debt To Equity	2.40 %
	Current Ratio	5.19 X
	Book Value Per Share	(2.26) X
	Cash Flow From Operations	(95.14 M)
	Short Ratio	13.03 X
	Earnings Per Share	(0.61) X
	Price To Earnings To Growth	(0.28) X
	Target Price	14.64
	Number Of Employees	536
	Beta	1.89
	Market Capitalization	1.51 B
	Total Asset	516.96 M
	Retained Earnings	(1.68 B)
	Working Capital	345.98 M
	Current Asset	65.99 M
	Current Liabilities	64.45 M
	Net Asset	516.96 M

About BioCryst Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioCryst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC